Ucar EY, et al. - This study assessed long-term outcomes including relapse, pulmonary hypertension (PH), mortality and hemorrhage among patients with pulmonary thromboembolism (PTE) treated with either 50 mg or 100 mg recombinant tissue-type plasminogen activator (rt-PA). Findings demonstrated that both doses of rt-PA displayed similar efficacy, however, patient selection may be responsible for the observed high mortality rate in the 50 mg group.